Arthritis, Rheumatoid
Conditions
Keywords
Rheumatoid Arthritis, Osteoclastogenesis inhibitor, Anti-Inflammatory Agent, Musculoskeletal Diseases, Joint Diseases
Brief summary
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments. MBS2320, the drug being tested in this trial, represents a new approach to treating RA, with the potential not only to reduce levels of inflammation but to also directly inhibit bone damage.The aim of this study is to test the safety of MBS2320 in healthy volunteers, to find out how MBS2320 levels change in the blood with dose, and to test the safety and compatibility of giving MBS2320 to patients with RA in combination with an existing treatment, methotrexate.
Detailed description
The study will be conducted in 4 parts (parts A to D). The principal aim of this study is to obtain safety and tolerability data when MBS2320 is administered orally as single and multiple doses to healthy subjects (parts A to C). The effect of MBS2320 on the pharmacokinetics (PK) of the first-line rheumatoid arthritis (RA) therapy, methotrexate (MTX), and the effect of MTX on the PK of MBS2320, will also be evaluated in a cohort consisting of subjects with RA (Part D).
Interventions
DRUGMBS2320
As described in the arm descriptions
DRUGPlacebo
As described in the arm descriptions
DRUGMethotrexate
Background therapy as described in the arm descriptions
Sponsors
Covance
Modern Biosciences Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Principal Inclusion Criteria: Parts A, B, and C. * Healthy males or females between 18 and 60 years of age. * A body mass index (BMI) between 18.0 and 30.0 kg/m2. * Female subjects will be of non-childbearing potential or postmenopausal as defined by the protocol. * Female subjects must not be pregnant. Part D * Subjects will be otherwise healthy males or females with a diagnosis of RA between 18 and 70 years of age. * Subjects will have a BMI between 18.0 and 30.0 kg/m2. * Female subjects must not be pregnant. * Subjects must have been treated with, and tolerated, oral or subcutaneous MTX for a minimum of 3 months prior to screening entry. Principal
Exclusion criteria
Parts A, B, and C. * Male subjects who do not agree to use appropriate contraception. * Female subjects who are receiving HRT who do not agree to use appropriate contraception. * Subjects who have donated blood in the 3 months, plasma in the 7 days or platelets in the 6 weeks prior to screening. * Subjects who consume more than the permitted alcohol requirement, who have a significant history of alcoholism or drug/chemical abuse. * Subjects who are unwilling to abstain from alcohol as required. * A positive urine drug screen, alcohol breath test at screening or first admission. * Subject has received a live virus vaccination within the 30 days prior to first dose administration. * Subjects with a positive test for tuberculosis. Additional Part D Exclusions * Subjects who have received any medication (except MTX) known to chronically alter drug absorption or elimination processes within 30 days prior to the first dose administration. * Subjects currently taking any medications other than those allowed per protocol guidelines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability (incidence of all grade adverse events and dose limiting toxicities during the observation period and/or study treatment periods) | Within 7 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Study Parts A, B and C - Area under the plasma concentration versus time curve (AUC) of MBS2320 | Part A and C - Up to 72hrs post dose, Part B - Up to 72 hrs post day 14 dose | — |
| Study Parts A, B and C Time to peak plasma concentration (Tmax) of MBS2320 | Part A and C - Up to 72hrs post dose, Part B - Up to 72 hrs post day 14 dose | — |
| Part D - Peak Plasma Concentration (Cmax) of MBS2320 and methotrexate | During the study treatment period | Half-life (T1/2) |
| Study Parts A, B and C - Peak Plasma Concentration (Cmax) of MBS2320 | Part A and C - Up to 72hrs post dose, Part B - Up to 72 hrs post day 14 dose | — |
| Part D - Time to peak plasma concentration (Tmax) of MBS2320 and methotrexate | During the study treatment period | — |
| Part D - Half-life (T1/2) of MBS2320 and methotrexate | During the study treatment period | — |
| Part D - Early response biomarkers of disease activity and bone turnover | Day 1 and 16. | CRP and CTX |
| Part D - Area under the plasma concentration versus time curve (AUC) of MBS2320 and methotrexate | During the study treatment period | Peak Plasma Concentration (Cmax), Area under the plasma concentration versus time curve (AUC), Time to peak plasma concentration (Tmax), Half-life (T1/2) |
Countries
United Kingdom
Outcome results
None listed